All In Biotech

Drug Trial Radar · NCT06562894

Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata

Last checked: Nov 20, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

May 26, 2025

Primary completion

May 31, 2027

Study completion Nov 17, 2027

Sponsor

Sponsor type
Industry
Collaborators
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
First posted
Aug 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.

Conditions

  • Severe Alopecia Areata

Interventions

  • SYHX1901Drug

    Administered orally, once daily (QD)

  • PlaceboDrug

    Administered orally, once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with Alopecia Severity Score Tool (SALT) score < or = 20%Time frame: Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.